Neural stem cell transplantation in patients with progressive multiple sclerosis: an open-label, phase 1 study
Angela Genchi,Elena Brambilla,Francesca Sangalli,Marta Radaelli,Marco Bacigaluppi,Roberto Furlan,Annapaola Andolfo,Denise Drago,Cinzia Magagnotti,Giulia Maria Scotti,Raffaella Greco,Paolo Vezzulli,Linda Ottoboni,Marco Bonopane,Daniela Capilupo,Francesca Ruffini,Daniela Belotti,Benedetta Cabiati,Stefania Cesana,Giada Matera,Letizia Leocani,Vittorio Martinelli,Lucia Moiola,Luca Vago,Paola Panina-Bordignon,Andrea Falini,Fabio Ciceri,Anna Uglietti,Maria Pia Sormani,Giancarlo Comi,Mario Alberto Battaglia,Maria A. Rocca,Loredana Storelli,Elisabetta Pagani,Giuseppe Gaipa,Gianvito Martino
DOI: https://doi.org/10.1038/s41591-022-02097-3
IF: 82.9
2023-01-11
Nature Medicine
Abstract:Innovative pro-regenerative treatment strategies for progressive multiple sclerosis (PMS), combining neuroprotection and immunomodulation, represent an unmet need. Neural precursor cells (NPCs) transplanted in animal models of multiple sclerosis have shown preclinical efficacy by promoting neuroprotection and remyelination by releasing molecules sustaining trophic support and neural plasticity. Here we present the results of STEMS, a prospective, therapeutic exploratory, non-randomized, open-label, single-dose-finding phase 1 clinical trial (NCT03269071, EudraCT 2016-002020-86), performed at San Raffaele Hospital in Milan, Italy, evaluating the feasibility, safety and tolerability of intrathecally transplanted human fetal NPCs ( hf NPCs) in 12 patients with PMS (with evidence of disease progression, Expanded Disability Status Scale ≥6.5, age 18–55 years, disease duration 2–20 years, without any alternative approved therapy). The safety primary outcome was reached, with no severe adverse reactions related to hf NPCs at 2-year follow-up, clearly demonstrating that hf NPC therapy in PMS is feasible, safe and tolerable. Exploratory secondary analyses showed a lower rate of brain atrophy in patients receiving the highest dosage of hf NPCs and increased cerebrospinal fluid levels of anti-inflammatory and neuroprotective molecules. Although preliminary, these results support the rationale and value of future clinical studies with the highest dose of hf NPCs in a larger cohort of patients.
biochemistry & molecular biology,cell biology,medicine, research & experimental